Approfondimenti generali
ESMO Clinical Practice Guidelines: Haematological Malignancies [Apri]
American Society of Hematology (ASH) 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults [Apri]
NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia. Version 2.2021 [Apri] A service of the U.S. National Institutes of Health [Apri]
Referenze bibliografiche specifiche
DaverN, et al. Targeting FLT3 mutations in AML: review of current knowledge and evidenceLeukemia 2019; 33: 299–312 [Apri]
Mori M, et al. Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia. Invest New Drugs 2017; 35: 556–565 [Apri]
Lee LY, et al. Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor. Blood 2017; 129: 257–260 [Apri]
Perl AE, et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. Lancet Oncol2017; 18: 1061–1075 [Apri]